Literature DB >> 12719960

Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.

C Sánchez1, P B F Bergqvist, L T Brennum, S Gupta, S Hogg, A Larsen, O Wiborg.   

Abstract

OBJECTIVE: The pharmacological profile of escitalopram, the S-(+)-enantiomer of citalopram, was studied and compared with citalopram and the R-(-)-enantiomer, R-citalopram.
METHODS: Inhibition of the serotonin transporter (5-HTT) was studied in COS-1 cells expressing the human 5-HTT (h-5-HTT) and in rat brain synaptosomes. In vitro selectivity was studied relative to noradrenaline transporter (NAT) and dopamine transporter (DAT) function in rat brain synaptosomes, and affinities for other binding sites were determined. In vivo 5-HT activity was measured as inhibition of neuronal firing rate in rat dorsal raphe nucleus (DRN) and enhancement of 5-hydroxytryptophan (5-HTP)-induced behaviour (mouse and rat). Furthermore, studies were conducted in models of antidepressant (mouse forced-swim test), anxiolytic [foot-shock-induced ultrasonic vocalization (USV) in adult rats and mouse black and white box] and anti-aggressive activity (socially isolated mice).
RESULTS: Escitalopram inhibited 5-HTT functions approximately 2 times more potently than citalopram and at least 40 times more potently than R-citalopram. Escitalopram showed insignificant activity at other monoamine transporters and 144 other binding sites. Escitalopram inhibited 5-HT neuronal firing in DRN and potentiated 5-HTP-induced behaviours more potently than citalopram; R-citalopram was inactive. Escitalopram and citalopram, but not R-citalopram, reduced forced-swimming-induced immobility and facilitated exploratory behaviour in the black and white box. Escitalopram and citalopram inhibited USV potently; R-citalopram was several times less potent. Escitalopram, citalopram and R-citalopram inhibited aggressive behaviour weakly. Escitalopram and citalopram had very potent anti-aggressive effects when co-administered with l-5-HTP.
CONCLUSION: Escitalopram is a very selective 5-HT reuptake inhibitor. It is more potent than its racemate citalopram and is effective in animal models predictive of antidepressant and anxiolytic activities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719960     DOI: 10.1007/s00213-002-1364-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Startle-inducing acoustic stimuli evoke ultrasonic vocalization in the rat.

Authors:  M T Kaltwasser
Journal:  Physiol Behav       Date:  1990-07

2.  Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

Authors:  William J Burke; Ivan Gergel; Anjana Bose
Journal:  J Clin Psychiatry       Date:  2002-04       Impact factor: 4.384

Review 3.  Is the forced swimming test a suitable model for revealing antidepressant activity?

Authors:  F Borsini; A Meli
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 4.  Role of the serotonergic system in the forced swimming test.

Authors:  F Borsini
Journal:  Neurosci Biobehav Rev       Date:  1995       Impact factor: 8.989

5.  Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs.

Authors:  J De Vry; U Benz; R Schreiber; J Traber
Journal:  Eur J Pharmacol       Date:  1993-11-16       Impact factor: 4.432

6.  Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats.

Authors:  C. Sánchez
Journal:  Behav Pharmacol       Date:  1993-06       Impact factor: 2.293

7.  The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.

Authors:  J Hyttel; K P Bøgesø; J Perregaard; C Sánchez
Journal:  J Neural Transm Gen Sect       Date:  1992

8.  The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice.

Authors:  C Sánchez; J Arnt; J Hyttel; E K Moltzen
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

Authors:  Jack M Gorman; Andrew Korotzer; Guojin Su
Journal:  CNS Spectr       Date:  2002-04       Impact factor: 3.790

10.  Escitalopram: a second-generation SSRI.

Authors:  Michael J Owens; Jerrold F Rosenbaum
Journal:  CNS Spectr       Date:  2002-04       Impact factor: 3.790

View more
  62 in total

1.  In vivo investigation of escitalopram's allosteric site on the serotonin transporter.

Authors:  Karen E Murray; Kerry J Ressler; Michael J Owens
Journal:  Pharmacol Biochem Behav       Date:  2015-11-24       Impact factor: 3.533

2.  Systems genetics analysis of pharmacogenomics variation during antidepressant treatment.

Authors:  M B Madsen; L J A Kogelman; H N Kadarmideen; H B Rasmussen
Journal:  Pharmacogenomics J       Date:  2016-10-18       Impact factor: 3.550

3.  Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.

Authors:  Peng Zhang; George Cyriac; Theresa Kopajtic; Yongfang Zhao; Jonathan A Javitch; Jonathan L Katz; Amy Hauck Newman
Journal:  J Med Chem       Date:  2010-08-26       Impact factor: 7.446

4.  Chronic Escitalopram Treatment Does Not Alter the Effects of Neonatal Stress on Hippocampal BDNF Levels, 5-HT1A Expression and Emotional Behaviour of Male and Female Adolescent Rats.

Authors:  Lorena Henn; Natália C Zanta; Carlos Eduardo N Girardi; Deborah Suchecki
Journal:  Mol Neurobiol       Date:  2020-10-15       Impact factor: 5.590

5.  Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression.

Authors:  V Bhagya; B N Srikumar; T R Raju; B S Shankaranarayana Rao
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

6.  The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Authors:  Jacob P R Jacobsen; Per Plenge; Benjamin D Sachs; Alan L Pehrson; Manuel Cajina; Yunzhi Du; Wendy Roberts; Meghan L Rudder; Prachiti Dalvi; Taylor J Robinson; Sharon P O'Neill; King S Khoo; Connie Sanchez Morillo; Xiaodong Zhang; Marc G Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

7.  Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression.

Authors:  Karim Malki; Maria Grazia Tosto; Héctor Mouriño-Talín; Sabela Rodríguez-Lorenzo; Oliver Pain; Irfan Jumhaboy; Tina Liu; Panos Parpas; Stuart Newman; Artem Malykh; Lucia Carboni; Rudolf Uher; Peter McGuffin; Leonard C Schalkwyk; Kevin Bryson; Mark Herbster
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-10-01       Impact factor: 3.568

8.  Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons.

Authors:  Charles H K West; James C Ritchie; Katherine A Boss-Williams; Jay M Weiss
Journal:  Int J Neuropsychopharmacol       Date:  2008-10-27       Impact factor: 5.176

9.  Long-term citalopram maintenance in mice: selective reduction of alcohol-heightened aggression.

Authors:  Elizabeth E Caldwell; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2007-10-20       Impact factor: 4.530

10.  Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat.

Authors:  Guillaume Lucas; Jenny Du; Thomas Romeas; Ouissame Mnie-Filali; Nasser Haddjeri; Graciela Piñeyro; Guy Debonnel
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.